Peptide Sciences Review: Scoring the Biggest Vendor That No Longer Exists

In December 2025, Peptide Sciences processed $7.4 million in revenue. Over one million sessions hit their site that month. On March 6, 2026, at roughly 2PM Eastern, they posted a three-sentence shutdown notice and disappeared.

This is a post-mortem peptide sciences review. We scored the Henderson, Nevada vendor across 123 independently tested samples, covering 10 peptides from a catalog that once listed over 100 compounds. The overall grade: B- (6.8/10). Solid legacy peptides. Critical failures on newer compounds. And one confirmed counterfeit.

The testing data below includes batches that contained zero retatrutide, the regulatory timeline that made shutdown inevitable, and a warning about copycat domains already harvesting former customers. Domain registered in 2009, operational for over a decade, with peak monthly traffic exceeding one million sessions. That history deserves a rigorous autopsy, scored against our methodology.

Ipamorelin scored 9.2 out of 10 across nine independent tests. CJC-1295 scored 4.3 out of 10 across ten. Same vendor. Same website. Same checkout page.

Peptide Sciences’ legacy compounds, the ones with stable supply chains and years of manufacturing precedent, performed well. Ipamorelin earned an A rating (9.2/10, 9 tests) with tight batch-to-batch consistency. PT-141 earned an A (9.1/10, 6 tests). BPC-157 held an A at 7.8/10 across 13 samples, their most-tested peptide. GHK-Cu landed a B (8.1/10).

The middle tier was more complicated. Semaglutide scored a B (7.5/10) across 15 samples, respectable but inconsistent batch to batch. Melanotan II dropped to a C at 6.4/10.

Then the failures. Tirzepatide earned a D (6.3/10, 15 samples). CJC-1295 collapsed to an E (4.3/10, 10 samples). Tesamorelin scored an E at 4.9/10.

Retatrutide crossed from inconsistent to dangerous. Across 37 samples, it earned an E rating. In November 2025, counterfeit batches were identified. Batch IDs RET7920231109-6 and RET7920231124-6 contained no retatrutide whatsoever and scored 2.0 out of 10. Quantity variance across all retatrutide samples ranged from -23.1% to +45.8%. Tom Howard published a public service announcement flagging the fakes.

The pattern across all 123 samples: established peptides with mature supply chains scored well. Newer, high-demand compounds where profit margins were highest and sourcing was murkiest failed consistently. MagellanRx confirmed that Peptide Sciences’ COA testing was internal only. Those certificates of analysis were marketing documents, not independent verification. Internal-only testing is also how counterfeit retatrutide made it to customers unchecked. For more on why that distinction matters, see our COA verification breakdown.

BPC-157 5mg cost $59.50 at Peptide Sciences. The 10mg vial ran $100. Meanwhile, EZ Peptides sells BPC-157 5mg for $35, and Ascension offers 10mg for $60, both with batch-specific COAs from named third-party labs.

The rest of the catalog followed the same pattern. TB-500 5mg at $85. PT-141 10mg at $55. AOD-9604 6mg for $65. NAD+ 750mg hit $300. Across popular peptides, Peptide Sciences ran 40-65% above market rates.

The brand premium was built on longevity and catalog breadth, not testing infrastructure. Over a decade of operation and 100+ listed compounds created a perception of quality that pricing reflected. MagellanRx gave the price-to-value ratio a 7.0/10, noting the gap between what customers paid and what verification they received in return.

Andrew Huberman flagged another issue: Peptide Sciences accepted Venmo as payment. For a vendor billing itself as the premium option in the research peptide space, a peer-to-peer payment app raised questions about operational maturity.

Premium pricing is defensible when backed by premium verification. Skye Peptides and BioLongevity Labs demonstrate what that looks like with named labs and batch-specific transparency. Peptide Sciences charged more and verified less. On retatrutide, customers paid premium prices for confirmed counterfeits.

The shutdown looked sudden. It was not. A 15-month regulatory escalation made the endpoint predictable for anyone paying attention.

December 2024: the FDA issued warning letters to Prime, Xcel, SwissChems, and Summit. January 2025: the ITC General Exclusion Order blocked tirzepatide imports, cutting off a major supply pipeline. By April 2025, Eli Lilly was suing telehealth companies directly. GLP-1 compounds were worth protecting.

June 2025 marked the first physical enforcement when the FDA raided Amino Asylum. August brought Novo Nordisk suing 14 defendants in a single filing. September escalated further: over 50 FDA warning letters with DOJ involvement, and reports confirmed the FDA was deploying AI tools to scrape vendor websites for compliance violations.

November 2025 hit Peptide Sciences directly. Counterfeit retatrutide was detected in their supply chain.

December 2025 set criminal precedent. Paradigm Peptides entered guilty pleas. Tailor Made Compounding forfeited $1.79 million. All American Pharmaceutical faced over $3 million in penalties. Seven or more vendors shut down during 2025. Chinese peptide imports had doubled to $328 million, and independent analyses found 40% of online peptides contained incorrect dosages.

Then the plot twist. On February 27, 2026, RFK announced on Joe Rogan episode #2461 that 14 banned peptides were being reclassified. One week later, on March 6, 2026, Peptide Sciences closed.

Huberman had warned that the “gray market is about to get CRUSHED.” Jay Campbell stated flatly: “Anything injectable is now toast.” LumaLex Law called it the most aggressive crackdown the industry had ever seen. The regulatory noose tightened for 15 months. Peptide Sciences was simply the biggest name caught inside it.

If you search for Peptide Sciences today, you will find a site that looks like it reopened. It did not.

The original domain was peptidesciences.com (singular “sciences”). That site is shut down. Before closing, Peptide Sciences explicitly warned customers about copycat operations.

The impersonator is peptidessciences.com (plural “peptides sciences,” note the extra S). This is a separate entity with no verified connection to the original vendor. It carries a 2.2 out of 5 rating on Trustpilot across 23 reviews. A second domain, peptidesciences.org, has also been flagged on Scamadviser.

Cremieux warned that the Peptide Sciences brand may attempt to reopen under a new name or through a different entity, making domain verification critical in the coming months.

Protect yourself. Verify domain spelling character by character. Check Trustpilot review histories for age and consistency. Use vendors scored through a transparent methodology rather than brand recognition from a company that no longer exists.

Do not send money to a domain that added a letter.

Two weeks before Peptide Sciences shut its doors, the regulatory landscape shifted in a direction that changes the calculus for former customers.

On February 27, 2026, RFK appeared on Joe Rogan Experience episode #2461 and announced that 14 of 19 Category 2 peptides would be reclassified to Category 1. The affected compounds include BPC-157, TB-500, CJC-1295, Ipamorelin, AOD-9604, Selank, and Semax. These were Peptide Sciences’ bread and butter.

Category 1 does not mean over-the-counter. It does not mean research-label legal. Category 1 means a compounding pharmacy can produce the peptide with a physician’s prescription. You will need a doctor and a licensed compounder.

Dr. Murphy called the reclassification “something quietly seismic.” The shift creates a legal, regulated pathway that did not exist six months ago, but it is a clinical pathway, not a consumer one.

Formal FDA publication of the reclassification was still pending as of March 2026. Until that publication, the regulatory status remains in limbo. The vendors page lists every vendor we have tested, and Skye Peptides and BioLongevity Labs both carry methodology-verified ratings.

The grey-market model that Peptide Sciences pioneered for over a decade may become obsolete within a year. Legal, pharmacy-grade peptides with real oversight could replace what the research market built in the regulatory gaps.

Peptide Sciences earns a B-. Not bad. Not what the reputation suggested.

The vendor earned its place in the market. Ten-plus years of operation, over 100 peptides, and genuinely strong results on legacy compounds like Ipamorelin (A) and PT-141 (A). That track record is real.

What held it back is equally real. Premium pricing without premium verification. E ratings on three peptides. Confirmed counterfeit retatrutide across multiple batches. Venmo as a payment method. A zero-notice shutdown that left active customers with no recourse, no refund process, and no communication.

Peptide Sciences helped establish the research peptide market. It gave the space credibility and scale when few options existed. But the market matured, and vendors with better transparency, lower prices, and named third-party labs overtook it. The reputation outran the verification.

For researchers looking forward: check our vendors page for scored alternatives, read the methodology to understand how we test, and stay away from copycat domains. The original Peptide Sciences is gone. What comes next should be better.

Is Peptide Sciences still open?

No. Peptide Sciences shut down on March 6, 2026, posting a three-sentence notice on their website. Any site claiming to be Peptide Sciences is a separate entity not connected to the original vendor.

Was Peptide Sciences legit?

Yes, Peptide Sciences was a real vendor operating for over a decade with a B- score (6.8/10). Testing results were mixed: strong on established peptides like Ipamorelin (A, 9.2/10) but poor on newer compounds like retatrutide (E, with confirmed counterfeits).

Why did Peptide Sciences close?

A 15-month regulatory escalation starting with FDA warning letters in December 2024, followed by ITC import orders, pharma lawsuits, and criminal prosecutions. Seven or more vendors shut down during 2025. Peptide Sciences followed in March 2026.

Is peptidessciences.com the same as Peptide Sciences?

No. The original domain was peptidesciences.com (singular). The site peptidessciences.com (plural, extra S) is a separate entity with no verified connection. It holds a 2.2/5 Trustpilot rating across 23 reviews. Peptide Sciences warned against copycat domains before closing.

What were Peptide Sciences’ testing results?

Mixed across 123 samples and 10 peptides. Top performers: Ipamorelin A (9.2/10), PT-141 A (9.1/10), BPC-157 A (7.8/10). Failures: CJC-1295 E (4.3/10), Tesamorelin E (4.9/10), and retatrutide E with confirmed counterfeit batches scoring 2.0/10.

What are the best Peptide Sciences alternatives?

Our vendors page lists every vendor scored through our testing methodology. Start there rather than relying on brand recognition from a vendor that no longer operates.

Was Peptide Sciences expensive?

Yes. BPC-157 5mg cost $59.50 versus $35 at competitors with batch-specific third-party COAs. Across popular peptides, pricing ran 40-65% above market rates. The premium reflected brand longevity, not superior testing infrastructure.

Are peptides legal again after the RFK announcement?

Partially. RFK announced 14 peptides moving from Category 2 to Category 1, but Category 1 means compounding pharmacy plus physician prescription. This is not over-the-counter access. Formal FDA publication was still pending as of March 2026.